RSV Human Challenge Models
Healthy participants 18-55 year old
Older Adults aged 60-75 years old
Conducted a number of human RSV challenge studies for a range of customers:
- Currently, the only RSV challenge model commercially available
- Healthy participant model utilised across multiple studies with vaccines and antivirals directed towards RSV
- RSV challenge model available in Older Adults (60-75) – targets population associated with significant unmet need in RSV
As the industry leader in conducting human viral challenge studies, we have developed a large Virobase, of clinical data paired with virological data, host genetics and immunology combined with an extensive biorepository of blood and respiratory samples. This “Virometrics” resource, in conjunction with our unique insight into the host response to viral disease, allows us to tailor study designs to each IMP.
Antivirals/Treatments
Conceptual Challenges:
- Testing proof of concept in the target population (pediatrics or elderly)
- Correlates of infection are poorly understood
- Lack of fully translatable immunogenicity animal models
Our Human Challenge Models: Towards a deeper understanding
Study design matched to investigational product mechanism of actions.
- Optimisation of treatment timing
- Time-dependent measurements of biomarkers
- Triggered-dosing options (time or virological)
- Controlled strain exposure
- Consistent placebo response
- Efficient resistance monitoring
Immunomodulators
Conceptual Challenges:
- Limited RSV immunomodulators in development
- Limited focus on adult/elderly populations
Our Human Challenge Models: Towards a deeper understanding
- Well controlled quarantine environments
- Baseline well established prior to infection
- Appropriate for both prophylaxis and treatment
- Flexible dosing and timing
- Establish safety & efficacy to impact infected subjects host response
- Investigate and demonstrate target engagement
- Controlled combination-treatment with drug and standard of care
Related Resources
Explore our blogs and resources on Virus & Bacteria Production & Characterisation for Human Challenge Trials, covering GMP manufacturing and scientific characterisation approaches used to develop safe, infectious challenge agents for high-fidelity clinical studies.
From RSV to hMPV: Building the Next Generation of Respiratory Challenge Models
Controlled Human Infection Model's (CHIM) in your backpack: how Human Challenge Trials support regulatory approval of travel vaccines
Unravelling the hMPV Surge: From Media Attention to Vaccine Development
Why are Biotech’s & Pharma Using Human Challenge Studies for Drug Development?
Tripledemic Takedown: How Human Challenge Trials are Ideal to Expedite Multivalent Vaccine Development
Empowering Next‑Gen Infectious Disease & Vaccine Development
Human Challenge Studies: Their Conduct and Safety Aspects
Human Challenge Trials as a tool in raising funding
UK Life Sciences Sector Plan 2025: What it Means for the Future of Clinical Research
The UK Regulatory Competitiveness in an ever changing world
